- Home
- About
- Team
- Today's Market
- Premium
- Research it
- Outlook
- Portfolio
- Mobile
- Trust Equitymaster
- Help
- Free Reports
MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Stock Quote (indian pharma)
- CIPLA
CIPLA Share Price 
(CIPL)
Here is the latest stock price and chart of Cipla. For more details, see the Cipla company fact sheet and quarterly results. For a sector overview, read our pharmaceuticals sector report.
| Live BSE Quotes | Aug 17, 2018 (Close) | ||
|---|---|---|---|
| Price (Rs)648.15 | Open (Rs) 651.80 | High (Rs) 655.00 | Low (Rs) 645.00 |
| % Change0.12 | Volume 112,530 | Value (Rs) 73,153,527 | 52-Week H/L 663.00 / 508.10 |
| Live NSE Quotes | Aug 17, 2018 (Close) | ||
|---|---|---|---|
| Price (Rs)646.90 | Open (Rs) 650.05 | High (Rs) 655.50 | Low (Rs) 643.70 |
| % Change-0.22 | Volume 2,915,387 | Value (Rs) 1,896,098,617 | 52-Week H/L 663.40 / 507.20 |
| Valuation | |||
|---|---|---|---|
| EPS (Rs)* 16.27 | P/E Ratio (x) 39.83 | Market Cap (Rs m) 521,248.71 | P/BV (x) 3.66 |
| *Trailing 12 months earnings, excluding extraordinary / exceptional items. | BSE Sensex | CNX Nifty |
- Charts
-
S&P BSE SENSEX
PERIOD - Advanced Charts new
- Charts by TradingView
CIPLA Share Price Today:
CIPLA last traded price was up 0.1% to Rs 648.2 on the BSE. On the NSE, CIPLA last traded price was down 0.2% to Rs 646.9. The total volume of shares traded was 3.0 m.
Overall, the broader S&P BSE HEALTHCARE Index was up by 1.3%. And the benchmark S&P BSE SENSEX was at 37,947.9 (up 0.8%).
Over the last 30 days, the CIPLA share price is up 1.7%. And over the last one year, CIPLA share price is up 13.0%.
|
| |
Today's Market
Sensex Ends 284 Points Up; FMCG & Metal Stocks Top Gainers(Closing)
Indian share markets settled higher today taking cues from their Asian peers. At the closing bell, BSE Sensex ended up by 284 points.
Related Views On News
CIPLA Announces Quarterly Results (1QFY19); Net Profit Up 4.7% (Quarterly Result Update)
Aug 10, 2018 | Updated on Aug 10, 2018For the quarter ended June 2018, CIPLA has posted a net profit of Rs 4 bn (up 4.7% YoY). Sales on the other hand came in at Rs 39 bn (up 11.7% YoY). Read on for a complete analysis of CIPLA's quarterly results.
CIPLA Announces Quarterly Results (4QFY18); Net Profit Down 347.8% (Quarterly Result Update)
May 24, 2018 | Updated on May 24, 2018For the quarter ended March 2018, CIPLA has posted a net profit of Rs 2 bn (down 347.8% YoY). Sales on the other hand came in at Rs 37 bn (up 3.2% YoY). Read on for a complete analysis of CIPLA's quarterly results.
Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)
Nov 10, 2017Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.
Aster DM Healthcare (IPO)
Feb 10, 2018Should you subscribe to the IPO of Aster DM Healthcare Ltd?
Shalby Ltd. (IPO)
Dec 2, 2017Should you subscribe to the IPO of Shalby Ltd?
More Views on NewsMost Popular
This is a Must-Have Stock for Your Portfolio(The 5 Minute Wrapup)
Aug 8, 2018Tanushree just released the permanent wealth blueprint report. This report includes three safe and steady stocks. I like one in particular. Here's why
Trading in These Times: 8% Gains in 3 Days!(Profit Hunter)
Aug 9, 2018Here are 2 stocks you can buy right now! And there are plenty more opportunities to come...
Banks are Raising FD Rates and That's Good News(Vivek Kaul's Diary)
Aug 7, 2018Lending to the retail segment remains strong, whereas lending to the service sector has picked up dramatically.
Why HDFC Equity Fund Disappointed Its Investors(Outside View)
Aug 9, 2018Though popular, HDFC Equity Fund is not among the best performers anymore. Here is the reason behind its underperformance that has left investors disappointed.
HDFC AMC Makes 65% Listing Gains! Should It Attract Mutual Fund Investors?(Outside View)
Aug 8, 2018PersonalFN explains if investors should invest in schemes of HDFC Mutual Fund looking at the listing gains of HDFC AMC.
MoreTRACK CIPLA
- Track your investment in CIPLA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON CIPLA
CIPLA - TEVA PHARMA COMPARISON
COMPARE CIPLA WITH
OTHER USEFUL LINKS
MARKET STATS
|
| |
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.